Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 55Other hematologic neoplasm 39Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × pegaspargase × Plasma cell × Clear all
NCT00837200 2017-07-24

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Milton S. Hershey Medical Center

Phase 2 Terminated
13 enrolled 12 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡